- ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
This study looks at a new drug, pembrolizumab (Keytruda), combined with standard chemotherapy for a type of cancer called biliary tract cancer. It aims to see if this combination helps people live longer compared to chemotherapy alone. It's a large study, comparing the two treatments directly.
Ireland · Germany · Spain - ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carcinoma. A non-comparative randomized phase II study
This study looks at treating bile duct cancer after surgery. Patients will receive either standard chemotherapy (capecitabine) or a combination of chemotherapy and a newer immune-boosting drug (durvalumab, also known as Imfinzi). The main goal is to see if the new combination helps people stay cancer-free for longer.
France - recruitingPHASE1, PHASE2
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
This study is testing a new medicine called AZD8205, by itself or with other cancer drugs. It's for people with advanced cancers like breast, ovarian, or lung cancer, to see if it's safe and helps shrink tumours.
United States · Australia · Belgium